MGC Pharma Receives First Shipment Of CannEpil™ In The UK; Stock Up 16%!

MGC Pharmaceuticals Ltd (ASX: MXC), a leading cannabinoid bio-pharma company, is involved in delivering high-quality cannabinoids based pharmaceuticals products to markets of Australasia, Europe and North America.

The company announced today that the first shipments of its proprietary product for people suffering from epilepsy, CannEpil™ has arrived in the UK. CannEpil™ is an oral oil solution that is used in cases of Drug Resistant Epilepsy. The solution helps to soothe symptoms such as seizures resulting from epilepsy.

The product could now be immediately distributed to pharmacies or directly to medical patients. Doctors are now prescribing cannabis-derived products to treat drug resistant conditions. This means that the acceptance of such products has expanded in the UK. The doctors got the approval to prescribe cannabis-derived products post changes in the UK regulations on 1 November 2018.

A day before, MGC Pharmaceuticals partnered with Grow Biotech and IPS to get ready access to distribution channels in medical cannabis market of the UK. Initially, the two companies have already received the prescriptions in the UK for CannEpil™. This signifies that the doctors and pharmacies are increasingly recommending the cannabis-derived products in case of drug resistant conditions.

Grow Biotech PLC is a British headquartered company that is engaged in developing tools to close the gap between the present cannabis medicines and approved pharmaceutical standards. IPS Specials is involved in the production of unlicensed compounded medications for hospital pharmacists and dispensing doctors.

The principal products of the company and their respective uses are indicated in the below chart.

The Co-founder and Managing Director of MGC Pharma, Roby Zomer consider the arrival of the first shipment as the milestone achieved in the history of MGC Pharma. He commented that CannEpil™ has the ability to enhance the lives of people living with epilepsy.

The company had made a lot of announcements in April relating to its collaborations and partnerships with other companies.

Last week, the company also entered into strategic supply agreements with Health House International and Cannvalate. Both the companies are engaged in the distribution and logistics services of medicinal cannabis. The agreement allowed MGC Pharma to market its phytocannabinoid-based products under the Special Access Scheme.

On 17th April 2019, the company collaborated with YuShop Global, a Chinese e-commerce import platform to market its CBD based nutraceuticals in the Chinese health products market. MGS’s nutraceutical products contain high-grade phytocannabinoids.

MGC Pharmaceuticals Ltd received the permit to import CannEpil™ into the UK on 12th April 2019. The license enabled the company to distribute CannEpil™ in medicinal cannabis products market of the United Kingdom.

MGC Pharmaceuticals made public its 2019 commercialisation strategy on 2nd April 2019 that focussed on the two key divisions including Research & Development and Seed-to-Pharmacy Manufacturing.

The company’s stock gained by 16 per cent post the announcement of receiving its first shipment. The stock ended higher on ASX at AUD 0.058 on 7th May 2019 while it traded flat at AUD 0.050 yesterday.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK